PH12014502250B1 - Mycoplasma hyopneumoniae vaccine - Google Patents

Mycoplasma hyopneumoniae vaccine

Info

Publication number
PH12014502250B1
PH12014502250B1 PH12014502250A PH12014502250A PH12014502250B1 PH 12014502250 B1 PH12014502250 B1 PH 12014502250B1 PH 12014502250 A PH12014502250 A PH 12014502250A PH 12014502250 A PH12014502250 A PH 12014502250A PH 12014502250 B1 PH12014502250 B1 PH 12014502250B1
Authority
PH
Philippines
Prior art keywords
mycoplasma hyopneumoniae
hyopneumoniae vaccine
hyo
soluble portion
preparation
Prior art date
Application number
PH12014502250A
Other languages
English (en)
Other versions
PH12014502250A1 (en
Inventor
Jeffrey E Galvin
Gregory P Nitzel
John Keith Garrett
James R Ii Kulawik
Tracy L Ricker
Megan Marie Smutzer
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48087777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12014502250(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PH12014502250A1 publication Critical patent/PH12014502250A1/en
Publication of PH12014502250B1 publication Critical patent/PH12014502250B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PH12014502250A 2012-04-04 2014-10-03 Mycoplasma hyopneumoniae vaccine PH12014502250B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620165P 2012-04-04 2012-04-04
PCT/US2013/035083 WO2013152081A1 (en) 2012-04-04 2013-04-03 Mycoplasma hyopneumoniae vaccine

Publications (2)

Publication Number Publication Date
PH12014502250A1 PH12014502250A1 (en) 2014-12-15
PH12014502250B1 true PH12014502250B1 (en) 2014-12-15

Family

ID=48087777

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014502250A PH12014502250B1 (en) 2012-04-04 2014-10-03 Mycoplasma hyopneumoniae vaccine

Country Status (31)

Country Link
US (5) US9120859B2 (enExample)
EP (2) EP2833908B1 (enExample)
JP (1) JP6271502B2 (enExample)
KR (1) KR101747507B1 (enExample)
CN (1) CN104271154B (enExample)
AR (1) AR090611A1 (enExample)
AU (1) AU2013243535C1 (enExample)
BR (1) BR112014024533B1 (enExample)
CA (1) CA2869603C (enExample)
CL (1) CL2014002674A1 (enExample)
CO (1) CO7160026A2 (enExample)
CR (1) CR20140436A (enExample)
CY (1) CY1124982T1 (enExample)
DK (1) DK2833908T3 (enExample)
ES (1) ES2905302T3 (enExample)
GT (1) GT201400210A (enExample)
HR (2) HRP20220175T1 (enExample)
HU (1) HUE058321T2 (enExample)
LT (1) LT2833908T (enExample)
MX (2) MX336504B (enExample)
MY (1) MY166792A (enExample)
NI (1) NI201400117A (enExample)
PH (1) PH12014502250B1 (enExample)
PL (1) PL2833908T3 (enExample)
PT (1) PT2833908T (enExample)
RS (1) RS62881B1 (enExample)
RU (1) RU2644254C2 (enExample)
SI (1) SI2833908T1 (enExample)
TW (1) TWI602575B (enExample)
UA (1) UA114502C2 (enExample)
WO (1) WO2013152081A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
KR102355614B1 (ko) * 2012-12-28 2022-01-27 베링거잉겔하임베트메디카게엠베하 마이코플라스마 항원을 포함하는 면역원성 조성물
UA121193C2 (uk) 2012-12-28 2020-04-27 Бьорінгер Інгельхайм Ветмедіка Гмбх Спосіб одержання імуногенної композиції проти мікоплазми
DK2994162T3 (en) 2013-05-08 2021-06-21 Pharmgate Biologics Inc Vaccine for pcv2 og mycoplasma
CN104248759B (zh) * 2013-11-19 2017-05-10 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
UA116697C2 (uk) * 2013-11-21 2018-04-25 Агрікалчерал Текнолоджи Рісьоч Інстітьют Композиція для запобігання зараженню видами роду mycoplasma
EP3151838A4 (en) * 2014-06-04 2017-11-29 Izard, Ryan Methods and compositions for orally dosing postnatal swine
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
CN104324370B (zh) * 2014-09-30 2019-12-20 普莱柯生物工程股份有限公司 疫苗组合物及其制备方法和应用
CA3010537A1 (en) * 2016-01-07 2017-07-13 Universiteit Gent Vaccine strains of brachyspira hyodysenteriae
US10953084B2 (en) * 2016-03-23 2021-03-23 Intervet Inc. Combination vaccine against PCV2 and PRRS virus infection comprising albumin
CN106497850B (zh) * 2016-12-20 2019-10-29 天津瑞普生物技术股份有限公司 一种纯化猪肺炎支原体的方法
US11065324B2 (en) 2016-12-23 2021-07-20 Intervet, Inc. Combination vaccine for swine
US11744883B2 (en) * 2017-12-22 2023-09-05 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus
BR112021025021A2 (pt) * 2019-06-10 2022-05-03 Elanco Us Inc Formulações de meios de mycoplasma
WO2021018806A1 (en) * 2019-07-26 2021-02-04 Ceva Sante Animale Igg-depleted porcine serum and the uses thereof
JP7657287B2 (ja) * 2020-07-24 2025-04-04 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 組合せブタワクチン
KR20220168098A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168102A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168097A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168099A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168100A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168101A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
CN114134098A (zh) * 2021-12-15 2022-03-04 成都史纪生物制药有限公司 一种猪肺炎支原体的灭活方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
CA1267087A (en) 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
EP0263840A1 (de) 1986-03-13 1988-04-20 ZF FRIEDRICHSHAFEN Aktiengesellschaft Einrichtung zum bestrahlen von flüssigkeiten mit radioaktiven strahlen
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ES2052685T3 (es) 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (en) 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
ZA888209B (en) 1987-11-03 1990-07-25 Syntex Inc Vaccine adjuvant
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ZA906806B (en) 1989-08-31 1991-06-26 Ici Australia Operations Plants
EP0597852B2 (en) 1990-05-29 2005-08-10 Wyeth Holdings Corporation Swine pneumonia vaccine and method for the preparation thereof
US6113916A (en) 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
CA2103460C (en) 1991-06-06 2000-09-26 Gert Wensvoort Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
CA2116348C (en) 1991-08-26 2001-07-03 James E. Collins Sirs vaccine and diagnosis method
EP0610250B2 (en) 1991-10-14 2008-10-29 Intervet International BV Porcine reproductive respiratory syndrome (prrs) vaccine and diagnostic
DE69232969T2 (de) 1991-11-15 2004-08-05 Pfizer Inc. Methode zur herstellung von gram-negativen bakteriellen vakzinen
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
ATE365049T1 (de) 1994-05-10 2007-07-15 Wyeth Corp Abgeänderter, verbesserter brsv lebend- impfstoff
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) * 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
JP2001515467A (ja) 1996-12-20 2001-09-18 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム モラクセラ・カタラーリスのｕｓｐａ１及びｕｓｐａ２抗原
KR20010032493A (ko) 1997-11-26 2001-04-25 아이오와 스테이트 유니버시티 리서치 파운데이션, 인코퍼레이티드 재조합 미코플라스마 히오뉴모니아(Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ) 백신
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
CA2290220C (en) 1998-12-22 2013-11-19 Pfizer Products Inc. An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
US6632439B2 (en) 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
DK2842569T3 (da) 2001-07-02 2019-05-20 Zoetis Services Llc Vaccination i en dosis med Mycoplasma hyopneumoniae
JP2004537543A (ja) * 2001-07-02 2004-12-16 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
WO2004003161A2 (en) 2002-06-28 2004-01-08 Iowa State University Research Foundation, Inc. Immunogenic mycoplasma hyopneumoniae polypeptides
EP1651265B1 (en) * 2003-07-24 2008-04-23 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
US8449989B2 (en) 2003-10-17 2013-05-28 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
KR20070096019A (ko) 2005-01-13 2007-10-01 베링거잉겔하임베트메디카게엠베하 향상된 ｐｒｒｓ 백신
UA95458C2 (ru) * 2005-09-09 2011-08-10 Интервет Интернешонал Б.В. Вакцина против pcv-2 у mda-положительных поросят
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
CN102698263B (zh) 2005-12-29 2016-07-06 贝林格尔.英格海姆维特梅迪卡有限公司 多价pcv2免疫原性组合物和制备此类组合物的方法
PL2007419T3 (pl) 2006-04-10 2012-09-28 Intervet Int Bv Szczepionka przeciwko mykoplazmie i PRRSV
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
KR101225304B1 (ko) * 2007-11-06 2013-01-22 와이어쓰 엘엘씨 마이코플라스마 하이오뉴모니아에 비독성 항원보강된 살아있는 백신
EP2242511A4 (en) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
EP2356132A2 (en) 2008-10-16 2011-08-17 Pfizer Inc. Torque teno virus (ttv) isolates and compositions
ES2559445T3 (es) 2010-05-11 2016-02-12 Intervet International B.V. Vacuna contra Mycoplasma hyopneumoniae apta para la administración en presencia de anticuerpos de origen materno
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
HUE028877T2 (en) 2010-08-27 2017-01-30 Intervet Int Bv Test of biological activity of vaccine formulation
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
BR112014022067B1 (pt) 2012-03-07 2022-05-31 Ceva Sante Animale Composição compreendendo antígeno e lipopolissacarídeo
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CA2872789C (en) * 2012-05-17 2019-09-03 Zoetis Llc Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning

Also Published As

Publication number Publication date
AR090611A1 (es) 2014-11-26
EP2833908B1 (en) 2022-01-05
BR112014024533B1 (pt) 2021-06-01
NI201400117A (es) 2015-03-05
MX336504B (es) 2016-01-21
PT2833908T (pt) 2022-02-17
RU2014140107A (ru) 2016-05-27
CY1124982T1 (el) 2023-01-05
US20150284677A1 (en) 2015-10-08
PL2833908T3 (pl) 2022-03-21
EP4039271A1 (en) 2022-08-10
US20200330577A1 (en) 2020-10-22
US10206991B2 (en) 2019-02-19
CN104271154A (zh) 2015-01-07
US9120859B2 (en) 2015-09-01
WO2013152081A1 (en) 2013-10-10
AU2013243535C1 (en) 2018-03-01
CA2869603A1 (en) 2013-10-10
KR101747507B1 (ko) 2017-06-14
US11141472B2 (en) 2021-10-12
ES2905302T3 (es) 2022-04-07
CR20140436A (es) 2014-11-12
US20170209560A1 (en) 2017-07-27
DK2833908T3 (da) 2022-02-07
HK1207284A1 (en) 2016-01-29
HRP20220175T1 (hr) 2022-04-29
RS62881B1 (sr) 2022-03-31
CN104271154B (zh) 2018-09-04
UA114502C2 (uk) 2017-06-26
MX354756B (es) 2018-03-20
TWI602575B (zh) 2017-10-21
SI2833908T1 (sl) 2022-04-29
PH12014502250A1 (en) 2014-12-15
US9650600B2 (en) 2017-05-16
CL2014002674A1 (es) 2014-12-12
US10668139B2 (en) 2020-06-02
CO7160026A2 (es) 2015-01-15
CA2869603C (en) 2018-06-12
RU2644254C2 (ru) 2018-02-08
GT201400210A (es) 2015-06-02
TW201345550A (zh) 2013-11-16
AU2013243535B2 (en) 2017-10-19
US20190134176A1 (en) 2019-05-09
JP2015512448A (ja) 2015-04-27
JP6271502B2 (ja) 2018-01-31
EP2833908A1 (en) 2015-02-11
US20130266601A1 (en) 2013-10-10
HRP20140957A2 (hr) 2015-02-27
AU2013243535A1 (en) 2014-10-09
MX2014012014A (es) 2014-11-10
BR112014024533A2 (pt) 2017-08-08
HUE058321T2 (hu) 2022-07-28
LT2833908T (lt) 2022-02-25
MY166792A (en) 2018-07-23
KR20150003257A (ko) 2015-01-08

Similar Documents

Publication Publication Date Title
PH12014502250A1 (en) Mycoplasma hyopneumoniae vaccine
MY199179A (en) Pvc/mycoplasma hyopneumonieau combination vaccine
PH12014502252A1 (en) Pcv/mycoplasma hyopneumoniae/prrs combination vaccine
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
NZ710744A (en) Methods for increasing immunoglobulin a levels
MX2015010110A (es) Diseño de inmunogenos a base de linaje de celulas b con animales humanizados.
IN2015DN03026A (enExample)
PH12015501335A1 (en) Immunogenic composition comprising mycoplasma antigens
PL2569007T3 (pl) Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
BR112015020053B8 (pt) Composições para cuidado oral
MX2013010618A (es) Metodo para preparar conjugados glucïdicos de glicopeptidos antigenicos multiples.